Article Versions Notes

Liefeldt L, Waiser J, Bachmann F, Budde K, Friedersdorff F, Halleck F, Lachmann N, Peters R, Rudolph B, Ünlü S, et al. Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients. Journal of Clinical Medicine. 2024; 13(15):4305. https://doi.org/10.3390/jcm13154305

Liefeldt, Lutz, Johannes Waiser, Friederike Bachmann, Klemens Budde, Frank Friedersdorff, Fabian Halleck, Nils Lachmann, Robert Peters, Birgit Rudolph, Sinem Ünlü, and et al. 2024. "Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients" Journal of Clinical Medicine 13, no. 15: 4305. https://doi.org/10.3390/jcm13154305

Liefeldt, L., Waiser, J., Bachmann, F., Budde, K., Friedersdorff, F., Halleck, F., Lachmann, N., Peters, R., Rudolph, B., Ünlü, S., Wu, K., & Glander, P. (2024). Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients. Journal of Clinical Medicine, 13(15), 4305. https://doi.org/10.3390/jcm13154305